Spruce Biosciences' rare disease drug fails PhIIb, company to lay off staff End Points, 14 Mar 2024 Spruce Biosciences’ tildacerfont failed a Phase IIb test in adults with congenital adrenal hyperplasia (CAH) due to compliance…